Section Arrow
ZYME.NASDAQ
- Zymeworks
Quotes are at least 15-min delayed:2026/03/11 06:59 EDT
Pre Market
Last
 25.4
-0.06 (-0.24%)
Bid
25.02
Ask
28
High 25.63 
Low 25.4 
Volume 49 
Regular Hours (Closed)
Last
 25.46
+1.19 (+4.90%)
Day High 
28 
Prev. Close
24.27 
1-M High
25.755 
Volume 
1.70M 
Bid
25.02
Ask
28
Day Low
24.7 
Open
24.98 
1-M Low
22.07 
Market Cap 
1.83B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 24.1 
20-SMA 23.49 
50-SMA 23.83 
52-W High 28.49 
52-W Low 9.03 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.85/-1.52
Enterprise Value
1.84B
Balance Sheet
Book Value Per Share
4.25
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
105.97M
Operating Revenue Per Share
6.12
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LGVNLongeveron0.891+0.3611+68.14%-- 
Pre Market 0.821 -0.07 -7.86%
BRTXBioRestorative Therapies0.2848+0.05015+21.37%-- 
Pre Market 0.2559 -0.0255 -9.06%
QNCXQuince Therapeutics0.104-0.0025-2.35%-- 
Pre Market 0.1033 +0.0022 +2.18%
ACXPAcurx Pharmaceuticals2.9+0.945+48.34%-- 
Pre Market 3.43 +0.53 +18.28%
PLYXPolaryx Therapeutics Inc5.97+2.44+69.12%-- 
Pre Market 5.56 -0.41 -6.87%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.